Literature DB >> 15306183

Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

Nicolas Bousette1, Lisa Patel, Stephen A Douglas, Eliot H Ohlstein, Adel Giaid.   

Abstract

Urotensin II (U-II), a novel vasoactive peptide, possesses a wide range of cardiovascular effects. U-II binds a seven transmembrane spanning G-protein coupled receptor termed GPR14. In the present study, we have characterized U-II expression in both carotid and aortic atherosclerotic plaques. Using immunohistochemistry we demonstrated U-II immunoreactivity in endothelial, smooth muscle and inflammatory cells of both carotid and aortic plaques, with a clear propensity for intimal staining. Using quantitative real-time RT-PCR we observed both increased U-II and GPR14 mRNA expression in tissue extracts from abdominal aortic aneurysms. We also extended our PCR analysis to include leukocyte expression of U-II and GPR14. We found that lymphocytes were by far the largest producers of U-II mRNA. In contrast monocytes and macrophages were the largest producers of GPR14 mRNA, with relatively little expression in foam cells, lymphocytes, and platelets. Our findings qualitatively and quantitatively demonstrate increased expression of U-II in atherosclerosis with a large degree of inflammatory cell involvement. These findings suggest a possible role for U-II in the pathophysiology of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306183     DOI: 10.1016/j.atherosclerosis.2004.03.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  23 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease.

Authors:  San Bao Chai; Xue Min Li; Yong Zheng Pang; Yong Fen Qi; Chao Shu Tang
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 3.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

Review 4.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

5.  Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

Authors:  M Demirpence; A Guler; H Yilmaz; A Sayin; Y Pekcevik; H Turkon; A Colak; E M Ari; B Aslanipour; G U Kocabas; M Calan
Journal:  J Endocrinol Invest       Date:  2018-05-26       Impact factor: 4.256

6.  Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Authors:  Raffaella Vergura; Valeria Camarda; Anna Rizzi; Martina Spagnol; Remo Guerrini; Girolamo Calo'; Severo Salvadori; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

7.  Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice.

Authors:  Cheng-Hua Zhou; Ya-Ya Wan; Xiang-Hua Chu; Zheng Song; Shu-Hua Xing; Yu-Qing Wu; Xiao-Xing Yin
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

8.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Authors:  D J Behm; J J McAtee; J W Dodson; M J Neeb; H E Fries; C A Evans; R R Hernandez; K D Hoffman; S M Harrison; J M Lai; C Wu; N V Aiyar; E H Ohlstein; S A Douglas
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

9.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

10.  Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.